8-K: Onconetix Finalizes Separation with Former Chief Business Officer, Engages Consulting Services
Separation Agreement and Consulting Agreement
Onconetix, Inc. has entered into a separation agreement with its former Chief Business Officer, Erin Henderson, and engaged her consulting firm, The Aetos Group, for a three-month period.
Summary
- Onconetix, Inc. finalized a separation agreement with Erin Henderson, who resigned as Chief Business Officer effective December 21, 2023.
- As part of the agreement, Onconetix will engage The Aetos Group, a consulting firm founded by Ms. Henderson, for a three-month consulting period.
- The consulting agreement is effective from the date of the separation agreement and will run until April 25, 2024.
- The Aetos Group will receive a monthly fee of approximately $27,083.33 for their services.
- Ms. Henderson's employment agreement includes post-employment restrictive covenants that remain in effect.
- The separation agreement includes mutual releases of claims, with exceptions for indemnification and D&O insurance coverage.
- Ms. Henderson will receive her final wages and benefits through December 31, 2023, with the option to continue health coverage under COBRA.
- The consulting services will focus on the transfer of corporate documents, communication of corporate history, and assistance with information transfer to corporate counsel.
Sentiment
Score: 6
Explanation: The document is neutral in tone, detailing a standard separation and consulting agreement. While the departure of a key executive is a negative, the engagement of a consulting firm provides a positive aspect. The overall sentiment is slightly positive due to the structured approach to the transition.
Positives
- The company has finalized the separation with its former Chief Business Officer.
- The company has secured consulting services from The Aetos Group to ensure a smooth transition.
- The separation agreement includes mutual releases, limiting future legal liabilities.
- The company has a clear plan for the transfer of corporate knowledge and documents.
Negatives
- The departure of the Chief Business Officer may create a temporary gap in leadership.
- The company will incur consulting fees of approximately $27,083.33 per month for three months.
- The company is relying on a consultant who was previously an employee, which could present conflicts of interest.
Risks
- The company may face challenges in the transition period following the departure of the Chief Business Officer.
- There is a risk of potential conflicts of interest due to the consulting agreement with the former officer's firm.
- The company may face legal challenges if the terms of the separation agreement are not strictly adhered to.
- The company may face challenges if the consulting services are not effective in transferring corporate knowledge and documents.
Future Outlook
The company will rely on The Aetos Group for consulting services for the next three months to ensure a smooth transition following the departure of the Chief Business Officer.
Management Comments
- The company acknowledges and accepts Ms. Henderson's resignation.
- The company acknowledges that the Indemnification Agreement and D&O Insurance coverage for Ms. Henderson will remain in effect.
- The company will provide a neutral reference for Ms. Henderson to prospective employers.
Industry Context
The departure of a key executive and subsequent engagement of a consulting firm is a common practice in the corporate world to ensure business continuity and knowledge transfer. This is especially relevant in the biotech industry where specialized knowledge is critical.
Comparison to Industry Standards
- The use of a separation agreement and a consulting agreement is a standard practice when a senior executive departs a company.
- The three-month consulting period is a typical duration for such engagements, allowing for a reasonable transition period.
- The monthly consulting fee of approximately $27,083.33 is within the range of market rates for similar consulting services.
- The restrictive covenants in the employment agreement are standard practice to protect the company's interests.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Business Officer | Erin Henderson | NA | December 21, 2023 | Resignation |
Related Party Transactions
- The consulting agreement with The Aetos Group, a company founded by the former Chief Business Officer, is a related party transaction.
Stakeholder Impact
- Shareholders may be concerned about the departure of a key executive, but the consulting agreement may provide reassurance.
- Employees may experience changes in workflow and responsibilities during the transition period.
- Customers and suppliers may not be directly impacted by this change.
- Creditors may not be directly impacted by this change.
Next Steps
- The Aetos Group will begin providing consulting services to Onconetix.
- Onconetix will pay The Aetos Group a monthly fee of approximately $27,083.33.
- Onconetix will ensure the transfer of corporate documents and information.
- Onconetix will continue to adhere to the terms of the separation agreement.
Key Dates
| Date | Description |
|---|---|
| February 23, 2022 | Date of the original Employment Agreement between Erin Henderson and Blue Water Vaccines, Inc. |
| December 21, 2023 | Effective date of Erin Henderson's resignation as Chief Business Officer. |
| December 31, 2023 | Date through which Erin Henderson will receive health coverage from the company. |
| January 17, 2024 | Date of the Separation Agreement and Consulting Agreement. |
| January 19, 2024 | Date by which Erin Henderson must return the signed Separation Agreement. |
| April 25, 2024 | End date of the consulting agreement with The Aetos Group. |
Keywords
separation agreement, consulting agreement, chief business officer, management consulting, restrictive covenants, mutual release, Onconetix, Erin Henderson, The Aetos Group
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.